Literature DB >> 9552382

A temporal and biochemical link between growth factor-activated MAP kinases, cyclin D1 induction and cell cycle entry.

J N Lavoie1, N Rivard, G L'Allemain, J Pouysségur.   

Abstract

Cell cycle re-entry requires the growth factor-stimulation of at least two distinct classes of protein kinases: (i) the p42/p44 MAP kinases activated by the Ras > Raf > MKK cascade and (ii) the G1 cyclin-dependent protein kinases (CDKs). Specific inactivation of either class of kinase arrests fibroblasts in G1. Growth factors promote nuclear translocation and persistent activation of p42/p44 MAP kinases during the entire G0/G1 period. Here, we demonstrate that induction of cyclin D1, and therefore cdk4/6 activity associated with, is positively controlled by the p42/p44 MAP kinase cascade whereas the parallel cytokines/stress-activated p38MAP kinase cascade is antagonistic. Finally, using an antisense approach we demonstrate that p27Kip1 plays a key role in setting the growth factor-dependency of the G0 state.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9552382     DOI: 10.1007/978-1-4615-5873-6_5

Source DB:  PubMed          Journal:  Prog Cell Cycle Res        ISSN: 1087-2957


  32 in total

1.  The mitogen-activated protein kinase kinase/extracellular signal-regulated kinase cascade activation is a key signalling pathway involved in the regulation of G(1) phase progression in proliferating hepatocytes.

Authors:  H Talarmin; C Rescan; S Cariou; D Glaise; G Zanninelli; M Bilodeau; P Loyer; C Guguen-Guillouzo; G Baffet
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

2.  SSeCKS, a major protein kinase C substrate with tumor suppressor activity, regulates G(1)-->S progression by controlling the expression and cellular compartmentalization of cyclin D.

Authors:  X Lin; P Nelson; I H Gelman
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

3.  Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.

Authors:  A E Lenferink; J F Simpson; L K Shawver; R J Coffey; J T Forbes; C L Arteaga
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

4.  Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation.

Authors:  Benjamin B Davis; David A Thompson; Laura L Howard; Christophe Morisseau; Bruce D Hammock; Robert H Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-12       Impact factor: 11.205

5.  Cell proliferation in in vivo-like three-dimensional cell culture is regulated by sequestration of ERK1/2 to lipid rafts.

Authors:  R Skrobanska; A Evangelatov; N Stefanova; T Topouzova-Hristova; A Momchilova; R Pankov
Journal:  Cell Prolif       Date:  2014-05-24       Impact factor: 6.831

6.  Mechanism in the sequential control of cell morphology and S phase entry by epidermal growth factor involves distinct MEK/ERK activations.

Authors:  C Rescan; A Coutant; H Talarmin; N Theret; D Glaise; C Guguen-Guillouzo; G Baffet
Journal:  Mol Biol Cell       Date:  2001-03       Impact factor: 4.138

Review 7.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

Authors:  Alison Donnelly; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

8.  Extracellular signal-regulated kinase 2 is necessary for mesoderm differentiation.

Authors:  Yao Yao; Wei Li; Junwei Wu; Ursula A Germann; Michael S S Su; Keisuke Kuida; Diane M Boucher
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-17       Impact factor: 11.205

9.  Premature centromere division of the X chromosome in neurons in Alzheimer's disease.

Authors:  Biljana Spremo-Potparević; Lada Zivković; Ninoslav Djelić; Bosiljka Plećas-Solarović; Mark A Smith; Vladan Bajić
Journal:  J Neurochem       Date:  2008-07-09       Impact factor: 5.372

Review 10.  Cancer stem cells and the ontogeny of lung cancer.

Authors:  Craig D Peacock; D Neil Watkins
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.